Exhibit 99.2

                              FOR IMMEDIATE RELEASE

      BOSTON LIFE SCIENCES ANNOUNCES ELECTION OF DR. ROBERT J. ROSENTHAL AS
                            CHIEF EXECUTIVE OFFICER

March 12, 2003 Boston, MA--Boston Life Sciences, Inc. (NASDAQ: BLSI) announced
today that Dr. Robert J. Rosenthal has been elected to the position of Chief
Executive Officer by the Board of Directors. David Hillson, the Company's
Chairman and current Chief Executive Officer, noted "Since joining the Company
last July, Dr. Rosenthal has been able to fully integrate himself into the
Company's operations, and is now well positioned to assume an expanded
leadership role in the organization. Bob's diverse operating experience should
prove critical as the Company's focus continues to migrate from a research
orientation to a greater emphasis on commercial opportunities for our products,
including partnering." Mr. Hillson will remain Chairman of the Board of
Directors.

BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease
(PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments
for cancer, autoimmune disease, and central nervous system disorders. BLSI's
products in development include: ALTROPANETM and FLUORATECTM radioimaging agents
for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring
anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine,
nerve growth factors for the treatment of acute and chronic CNS disorders; novel
therapies for the treatment of PD and ADHD; and transcription factors that may
control the expression of molecules associated with autoimmune disease and
allergies.

Statements made in this press release other than statements of historical fact
represent forward-looking statements. Such statements include, without
limitation, statements regarding expectations or beliefs as to future results or
events, such as the expected timing and results of clinical trials, discussions
with regulatory agencies, schedules of IND, NDA and all other regulatory
submissions, the timing of product introductions, the possible approval of
products, and the market size and possible advantages of the Company's products.
All such forward-looking statements involve substantial risks and uncertainties,
and actual results may vary materially from these statements. Factors that may
affect future results include: the availability and adequacy of financial
resources, the ability to obtain intellectual property protection, delays in the
regulatory or development processes, results of scientific data from clinical
trials, the outcome of discussions with potential partners, regulatory
decisions, market acceptance of the Company's products, and other possible risks
and uncertainties that have been noted in reports filed by the Company with the
Securities and Exchange Commission, including the Company's Annual Report on
Form 10-K.

     For further information, please contact:

                         Corporate
                         Joseph Hernon
                         Chief Financial Officer
                         Boston Life Sciences, Inc.
                         617.425.0200
                         jhernon@bostonlifesciences.com